Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company's leadership. At least 165 employees will be laid off, including 55% of the... — read more 

Less than a month after the U.S. Food and Dr-g Administration (FDA) gave its antidepressant dr-g zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its dr-g development efforts and... — read more